Physician profile
Kristin Held
NPI 1356303374
$2,007.34
in general payments reported to CMS, 2019-2025
14 companies · $653 in 2025
The $653 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $18.51 · 2021: $122 · 2022: $453 · 2023: $166 · 2024: $491 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.24 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $514.69 | 2024-2025 | |
| Alcon Vision LLC | $501.08 | 2021-2025 | Clareon, Total30 |
| Rxsight INC | $197.20 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $150.65 | 2019-2022 | |
| Astellas Pharma US INC | $127.12 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $116.78 | 2022-2023 | Cequa |
| Allergan, INC. | $103.25 | 2019-2022 | |
| Lensar, INC. | $101.16 | 2025 | Lensar Laser System |
| Abbvie INC. | $62.06 | 2025 | |
| Glaukos Corporation | $35.78 | 2024 | Radius |
| Bausch & Lomb Americas INC. | $32.94 | 2022-2023 | Lotemax, Zylet, Prolensa |
| Ocular Therapeutix, INC. | $28.17 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $18.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Held listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.